Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
Rhea-AI Summary
Firefly Neuroscience (NASDAQ: AIFF) announced a research advance on March 13, 2026: its AI-powered EEG/ERP platform using data from its FDA 510(k)-cleared Evoke System may help distinguish the three main ADHD subtypes.
The company cites a growing foundation model trained on over 191,000 brain scans, potential clinical uses for subtype-specific treatment guidance and monitoring, and access to NVIDIA GPU acceleration to speed EEG/ERP processing.
Positive
- FDA 510(k) clearance for the Evoke System
- Dataset >191,000 brain scans supporting model training
- Access to NVIDIA GPU acceleration for EEG/ERP processing
- Addresses a >$10 billion U.S. ADHD treatment market
Negative
- Discovery described as preliminary research and not presented as established diagnostic standard
- Company uses cautious language (may, potentially), so clinical utility and commercial impact remain unproven
Market Reaction – AIFF
Following this news, AIFF has gained 47.80%, reflecting a significant positive market reaction. Our momentum scanner has triggered 41 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.57. This price movement has added approximately $12M to the company's valuation. Trading volume is elevated at 2.5x the average, suggesting notable buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
Sector scanner shows 3 peers in momentum, with 2 moving down and 1 up; median peer move around sector is modestly negative, suggesting some broader software/AI pressure alongside this stock’s action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Commercial expansion | Positive | +126.3% | Reported major growth in users and EEG/ERP scan volumes with NVIDIA acceleration. |
| Nov 12 | Earnings update | Positive | +5.5% | Q3 2025 revenue growth, lower expenses, and reduced net loss after Evoke deal. |
Recent positive operational and financial updates have coincided with favorable next-day moves, including one triple‑digit percentage gain.
Recent news shows Firefly emphasizing commercialization and AI infrastructure alongside clinical applications. On Nov 12, 2025, Q3 2025 results highlighted revenue growth to $388,000, lower operating expenses, and reduced net loss, with a 5.45% next‑day gain. On Mar 04, 2026, news of a >20‑fold commercial footprint expansion and 10,800+ scans drove a 126.28% move. Today’s ADHD biomarker update extends that story of scaling EEG/ERP data and AI‑driven neuroscience.
Regulatory & Risk Context
An effective Form S-3 mixed shelf filed on Dec 03, 2025 registers up to $250,000,000 of securities, enabling periodic issuance of equity, debt, warrants, and units as detailed in future prospectus supplements. The company has already utilized the shelf via a $7,434,266 at‑the‑market equity facility, indicating capacity for additional capital raises that could affect share count over time.
Market Pulse Summary
The stock is surging +47.8% following this news. A strong positive reaction aligns with Firefly’s history of sharp moves on operational milestones, such as the prior 126.28% jump on platform expansion news. However, the presence of a $250,000,000 mixed shelf and an active ATM facility could introduce ongoing financing overhang. Investors have previously rewarded data-scale and AI advances, but future capital raises and overall sector sentiment could influence how durable such gains become.
Key Terms
eeg medical
erp medical
biomarker medical
AI-generated analysis. Not financial advice.
Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive1
Firefly’s AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has — potentially complementing subjective symptom checklists with neural signal-based precision
Subtype identification could change the clinical equation: Firefly’s platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working
The breakthrough advances Firefly’s mission to build the world’s first EEG/ERP brain foundation model — being trained on a growing repository of over 191,000 brain scans
KENMORE, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research using Resting EEG/Cognitive EEG (ERP) brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder (“ADHD”): hyperactive and impulsive, inattentive, and combined.2 ADHD represents a U.S. treatment market estimated at over
Today, a diagnosis of adult ADHD is based upon meeting the following general symptoms-based criteria: symptoms should be present in two or more settings, such as home, work or school; symptoms should clearly interfere with or reduce the functioning of a person in social, work, or school-related activities; symptoms experienced cannot be better explained by another mental health condition, such as depression or anxiety; and symptoms should not only occur during the course of a psychotic disorder like schizophrenia.4
In addition, healthcare professionals typically use the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) to distinguish between the three types of ADHD. According to the DSM-5, adult ADHD may be diagnosed in the following cases: (i) hyperactive and impulsive type ADHD - at least five symptoms of hyperactivity and impulsivity for more than six months without meeting the diagnostic criteria for inattentive behavior; (ii) inattentive type ADHD - at least five symptoms of inattention for more than six months without meeting the diagnostic criteria for hyperactive or impulsive behavior; and (iii), combined type ADHD - at least five symptoms of hyperactivity and impulsivity and at least five symptoms of inattention for more than 6 months.4
Gil Issachar, Chief Technology Officer of Firefly, commented, “While there has been significant progress made in the treatment of ADHD over the years, there is no question that significant unmet need remains, particularly after a general diagnosis of the disorder has been made. For example, some types of ADHD respond well to stimulants, while others don’t and neurofeedback therapy may be recommended instead.5 Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans. We believe that the technology also opens the door to ongoing treatment monitoring — allowing clinicians to objectively track whether an intervention is working at the neurological level.”
Firefly’s methodology is supported by prior peer-reviewed research, including a study published in Frontiers in Psychiatry, demonstrating the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients.6
Greg Lipschitz, Chief Executive Officer of Firefly, said, “This latest Firefly cognitive brain biomarker discovery serves as another demonstration of how we are harnessing the power of AI and EEG/ERP to potentially transform neuroscience and clinical development. Moving forward, armed with a growing foundation of brain scan data and important access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing, we believe that we are on the right path to making even more breakthroughs in cognitive brain biomarker discovery, as well as to fulfilling our goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
Sources
1 https://chadd.org/about-adhd/general-prevalence/
2 https://doi.org/10.1017/S0033291716003329
5 https://www.nature.com/articles/d41586-026-00095-w
6 https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1026616/full
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
What did Firefly (AIFF) announce on March 13, 2026 about ADHD subtype biomarkers?
How could Firefly's AI EEG findings affect ADHD treatment choices for AIFF investors?
Does Firefly have regulatory clearance for the technology used in the AIFF announcement?
How large is the dataset Firefly says it is using to build its EEG/ERP foundation model?
What role does NVIDIA play in Firefly's March 13, 2026 announcement (AIFF)?
Is Firefly's ADHD biomarker discovery ready for clinical diagnosis and use by physicians?
